HDAC inhibitors, including Panobinostat, SAHA, and Romidepsin, are extensively studied in prostate cancer treatment, with these agents currently undergoing clinical trials [29, 52, 53]. This evidence concerns the gene HDAC9 and Familial prostate cancer.